Table 3.

Multivariable cox proportional hazards regression analysis of first-line systemic therapy outcomes^†.

Variable	TTD		Systemic PFS		OS
	HR (95% CI)	Pr >ChiSq	HR (95% CI)	Pr >ChiSq	HR (95% CI)	Pr >ChiSq
First-line therapy (reference: capmatinib)
IO monotherapy	1.39 (0.78–2.48)	0.259	1.57 (0.77–3.20)	0.220	1.46 (0.40–5.29)	0.564
Chemotherapy alone	9.12 (5.26–15.79)	<0.0001	2.41 (1.19–4.85)	0.014	4.43 (1.54–12.75)	0.006
IO + chemotherapy	2.27 (1.46–3.54)	0.000	2.33 (1.35–4.04)	0.003	3.53 (1.41–8.85)	0.007
Age (continuous)	1.00 (0.98–1.02)	0.952	1.01 (0.98–1.03)	0.666	1.02 (0.98–1.06)	0.319
Female (reference: no)
Yes	0.77 (0.51–1.15)	0.196	0.89 (0.55–1.45)	0.653	0.67 (0.30–1.46)	0.310
Index year (reference: 2017–2020)
2021	1.31 (0.85–2.03)	0.218	N/A‡		0.72 (0.31–1.67)	0.445
2022	0.74 (0.42–1.31)	0.297			2.17 (0.68–6.94)	0.194
Insurance status (reference: commercial/private)
Medicare	0.49 (0.30–0.79)	0.003	N/A‡		1.16 (0.47–2.86)	0.751
All other and don't know	0.86 (0.52–1.43)	0.569			2.64 (1.08–6.49)	0.034
Healthcare setting type (reference: academic or teaching hospital)
Community or nonacademic hospital	N/A‡		0.56 (0.32–0.96)	0.036	N/A‡
Disease stage (reference: stage IIIB/ IIIC)
Stage IV	0.58 (0.40–0.84)	0.003	N/A‡		3.92 (1.78–8.65)	0.001
National Cancer Institute comorbidity score (reference: ≤1.35)
>1.35	1.44 (0.99–2.09)	0.054	N/A‡		2.34 (1.10–4.99)	0.027
ECOG (reference: 0)
1	1.74 (1.06–2.84)	0.027	0.96 (0.50–1.83)	0.892	3.10 (0.86–11.18)	0.083
2 or 3	2.70 (1.50–4.86)	0.001	2.05 (0.99–4.25)	0.054	8.64 (2.31–32.41)	0.001
Not recorded/don't know	1.13 (0.60–2.14)	0.708	0.73 (0.30–1.74)	0.475	7.41 (1.80–30.50)	0.006

Bold values indicate statistically significant results.

^‡Variable was not retained in the final model estimated via backward selection process.

HR: Hazard ratio; N/A: Not applicable; OS: Overall survival; PFS: Progression-free survival; TTD: Time to treatment discontinuation.